Brief: Sutro Biopharma Announces Positive Data From Use Luvelta In Pediatric Patients With Relapsed/Refractory Cbf/Glis

Sutro Biopharma

11/12/2023 21:54

Dec 11 (Reuters) - Sutro Biopharma Inc  STRO.O :
    * SUTRO BIOPHARMA ANNOUNCES NEW POSITIVE DATA FROM THE
COMPASSIONATE USE OF LUVELTAMAB TAZEVIBULIN (LUVELTA) IN
PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY CBF/GLIS PRESENTED
AT ASH 2023
    * SUTRO BIOPHARMA INC - LUVELTA WAS GENERALLY WELL-TOLERATED
    * SUTRO BIOPHARMA INC - DATA SUPPORTS POTENTIAL FURTHER
DEVELOPMENT IN CBF/GLIS AML
    * SUTRO BIOPHARMA -COMPLETE REMISSION IN 42% OF PATIENTS
WITH
CBF/GLIS AML WITH ≥5% BLASTS & 75% OF PEDIATRIC PATIENTS WITH
CBF/GLIS AML WITH <5% BLASTS

Source text for Eikon:  ID:nGNXxWsF4 
Further company coverage:  STRO.O 

 ((Reuters.Briefs@thomsonreuters.com;))